Article citationsMore >>

Feng Z. Pharmacokinetics and pharmacodynamics and pharmacodynamics of Sacubtril/Valsartan in maintenance hemodialysis patients with heart failure. Blood Purification: 51: 270-279, 2021.

has been cited by the following article:

Article

Sacubtril/valsartan in HFpEF and Maintenance Hemodialysis

1Department of Hemodialysis, Yonabaru Central Hospital, Yonabaru, Okinawa Prefecture, Japan


American Journal of Medical Case Reports. 2023, Vol. 11 No. 2, 14-15
DOI: 10.12691/ajmcr-11-2-1
Copyright © 2023 Science and Education Publishing

Cite this paper:
Noriko Kuwae, Masahiro Yamasato. Sacubtril/valsartan in HFpEF and Maintenance Hemodialysis. American Journal of Medical Case Reports. 2023; 11(2):14-15. doi: 10.12691/ajmcr-11-2-1.

Correspondence to: Noriko  Kuwae, Department of Hemodialysis, Yonabaru Central Hospital, Yonabaru, Okinawa Prefecture, Japan. Email: kwenon@gmail.com

Abstract

The purpose of this report is to describe effectiveness and tolerability of medical treatment with sacubitril/valsartan in a patient treated with hemodialysis. We describe the case of a 68-year-old man with heart failure with ejection fraction more than 60%, that is HFpEF undergoing hemodialysis. He had several times heart failure due to diastolic dysfunction, he could tolerate a dose of 50/50mg, total 100mg daily. After initiation of sacubitril/valsartan, there was a symptomatic improvement with clear reduction NT-proBNP, left atrial dimension, E/e’ as well as EF. In conclusion, in this patient with diastoric dysfunction undergoing hemodialysis, treatment with sacubitril/valsartan was effective, safe, and improved heart failure symptoms.

Keywords